NCT06885385View on ClinicalTrials.gov

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

November 27, 2026

Study Completion Date

February 13, 2027

Conditions
Advanced Colorectal Cancer
Interventions
BIOLOGICAL

JS207

JS207 will be administered every 3 weeks for a treatment cycle of 21 days

BIOLOGICAL

JS015

JS015 will be administered every 3 weeks for a treatment cycle of 21 days

DRUG

Capecitabine

Capecitabine of 1000mg/m2 will be administered orally twice daily from day 1 to 14 every 21 day cycle

DRUG

Oxaliplatin

Oxaliplatin of 130mg/m2 will be administered intravenously (IV) on day 1 every 21 day cycle

Trial Locations (2)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

200120

RECRUITING

Shanghai Oriental Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER